Research has linked depression with morbidity and mortality from chronic medical conditions. Given findings that depression is a mediator of smoking relapse, cigarette smoking provides fertile ground for research in this area. Smokers with a history of major depressive disorder (MDD) represent a significant proportion of smokers; these individuals experience more depressive symptoms upon cessation and higher relapse rates than other smokers. The proposed study will test the hypothesis that intensive treatment(s) intended to address depressive symptoms and negative mood will enhance the achievement and maintenance of smoking cessation in adult smokers with a history MDD. We will also examine the relationship between mood-related symptoms and smoking cessation outcomes. Finally, we will identify cognitive and behavioral mediators of the effects of depressive symptoms on smoking cessation. The study employs an additive randomized, double-blind, placebo-controlled design to test the incremental efficacy of: 1) standard smoking cessation treatment plus placebo, vs. 2) standard smoking cessation plus intensive cognitive- behavioral treatment for depression plus placebo, vs. 3) standard smoking cessation plus intensive cognitive-behavioral treatment for depression plus antidepressant (bupropion hydrochloride). All smokers will receive 14 group sessions of standard smoking cessation treatment, which includes 8 weeks of transdermal nicotine replacement. A sample of 396 subjects will be recruited to include only smokers with a positive history of MMD. Subjects will be treated for 12 weeks and followed for 12 months. Current and past psychiatric diagnoses will be assessed, as will changes in depressive symptoms and mood states. Smoking cessation outcomes will be validated by saliva cotinine. We expect that this study will result in the development of a specialized, efficacious treatment for the large percentage of smokers with past MMD, and will therefore have important clinical and public health significance in reducing the overall prevalence of cigarette smoking. We further expected that this study will increase our basic knowledge about the role of depressive symptoms, the effects of selected cognitive and behavioral mediators, and the interaction of pharmacological and psychosocial factors in the process of smoking cassation.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
2R01DA008511-05
Application #
2013170
Study Section
Human Development Research Subcommittee (NIDA)
Project Start
1993-03-01
Project End
2001-05-31
Budget Start
1997-07-01
Budget End
1998-05-31
Support Year
5
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Butler Hospital (Providence, RI)
Department
Type
DUNS #
069847804
City
Providence
State
RI
Country
United States
Zip Code
02906
Leventhal, A M; David, S P; Brightman, M et al. (2012) Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics J 12:86-92
Cohn, Amy M; Strong, David R; Abrantes, Ana M et al. (2010) History of single episode and recurrent major depressive disorder among smokers in cessation treatment: Associations with depressive symptomatology and early cessation failure. Addict Disord Their Treat 9:41-52
Li, Yimei; Wileyto, E Paul; Heitjan, Daniel F (2010) Modeling smoking cessation data with alternating states and a cure fraction using frailty models. Stat Med 29:627-38
Strong, David R; Kahler, Christopher W; Leventhal, Adam M et al. (2009) Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. Nicotine Tob Res 11:1142-53
Uhl, George R; Liu, Qing-Rong; Drgon, Tomas et al. (2008) Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 65:683-93
Uhl, George R; Drgon, Tomas; Johnson, Catherine et al. (2008) Molecular genetics of addiction and related heritable phenotypes: genome-wide association approaches identify ""connectivity constellation"" and drug target genes with pleiotropic effects. Ann N Y Acad Sci 1141:318-81
David, Sean P; Brown, Richard A; Papandonatos, George D et al. (2007) Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 9:821-33
Kassel, Jon D; Yates, Marisa; Brown, Richard A (2007) Baseline reaction time predicts 12-month smoking cessation outcome in formerly depressed smokers. Psychol Addict Behav 21:415-9
David, Sean P; Strong, David R; Munafo, Marcus R et al. (2007) Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res 9:1251-7
Brown, Richard A; Niaura, Raymond; Lloyd-Richardson, Elizabeth E et al. (2007) Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res 9:721-30

Showing the most recent 10 out of 26 publications